Nano-Mab Pharma

Nano-Mab Pharma is a clinical-stage biopharmaceutical company specializing in the development of next-generation radiopharmaceuticals using camelid-derived single-domain antibodies (sdAbs), also known as nanobodies. The company's platform leverages the small size and high specificity of nanobodies to create precision imaging agents and targeted radionuclide therapies for oncology. Their lead program, NM-01, is a PD-L1-targeted imaging agent designed to identify patients likely to respond to immunotherapy by visualizing PD-L1 expression in the tumor microenvironment. Nano-Mab operates with a global footprint, maintaining research and development facilities in China and the United Kingdom. By combining nanobody technology with radioactive isotopes, the company aims to provide theranostic solutions that improve cancer diagnosis and treatment outcomes.